US20050256080A1 - Method for reducing malodor of chondroitin - Google Patents
Method for reducing malodor of chondroitin Download PDFInfo
- Publication number
- US20050256080A1 US20050256080A1 US11/120,887 US12088705A US2005256080A1 US 20050256080 A1 US20050256080 A1 US 20050256080A1 US 12088705 A US12088705 A US 12088705A US 2005256080 A1 US2005256080 A1 US 2005256080A1
- Authority
- US
- United States
- Prior art keywords
- composition
- chondroitin
- weight
- percent
- canceled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/014—Deodorant compositions containing sorbent material, e.g. activated carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/013—Deodorant compositions containing animal or plant extracts, or vegetable material
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
Definitions
- the present invention relates to a method for the removal or masking of malodor from chondroitin derived from marine life.
- the present invention also relates to chondroitin compositions derived from marine life which lack a malodor.
- Chondroitin and glucosamine are chondroprotective agents used for the treatment of osteoarthritis and related diseases.
- Chondroitin sulfate is a soluble mucopolysaccharide derived from bovine, ovine or shark cartilage.
- Chondroitin sulfate derived from marine life, such as cartilage isolated from sharks, provides a rich, pure, and readily absorbed source of chondroitin.
- Chondroitin sulfate has been reported to be effective in tissue repair and cartilage regeneration. Combinations of glucosamine and chondroitin are also effective in cartilage regeneration and joint maintenance. Chondroitin and glucosamine appear to act by increasing chondrocyte anabolic activity and suppressing degradative action of mediators on cartilage. This appears to facilitate natural tissue repair. See, e.g., H. Benedikt, Nat. Pharm., 1(8): 1, 22 (1997) and C. Bassleer, et al., Int. J. Tiss. Reac. XIV(5): 231-241: (1992). Additionally, chondroitin and glucosamine are believed to be safer and less toxic than steroids or non-steroidal anti-inflammatory drugs commonly administered to treat arthritis and related musculo-skeletal diseases.
- shark cartilage is rich source of chondroitin
- shark-derived chondroitin has a strong malodor.
- compositions containing shark-derived chondroitin without its malodor and methods of preparing the same. Removal of the malodor associated with such chondroitin would improve consumer acceptability and enhance patient compliance.
- the invention relates to a method of removing or masking odor associated with chondroitin sulfate.
- the method comprises blending the chondroitin with citric acid, silicon dioxide, and, optionally a flavorant, to yield a substantially non-malodorous blend.
- the blend may be formed into a solid dosage form, such as a tablet.
- Another embodiment of the invention is a composition comprising chondroitin, citric acid, silicon dioxide, and an optional flavorant.
- the present inventors have discovered that the malodor associated with chondroitin derived from marine life may be removed or masked by blending the chondroitin with citric acid and silicon dioxide. Chondroitin compositions produced through the use of the present invention exhibit reduced levels of the malodor normally associated with such chondroitin compositions derived from marine sources
- the chondroitin may be any chondroitin-containing composition. Commonly available are two salts, namely chondroitin sulfate or chondroitin hydrochloride.
- the chondroitin is the sulfate salt and is derived from shark cartilage.
- the chondroitin is water soluble, such as Polychon 60/40 available from Vanson, Inc. (Pfanstiehl Laboratory Inc.) of Waukegan, Ill.
- the amount of citric acid in the composition broadly ranges from about 0.05 to about 10% percent by weight based upon 100 percent by weight of total composition. Preferably, the amount of citric acid in the composition is about 1.5 percent by weight on the same basis.
- the amount of silicon dioxide in the composition ranges broadly from about 0.01 to about 2.0 percent by weight based upon 100 percent by weight of total composition.
- the amount of silicon dioxide in the composition is preferably about 0.2 percent by weight on the same basis.
- compositions may be included in the composition.
- adjuvants as known to those in the art, such as disintegrants, antioxidants, lubricants and binders, may be included in the composition.
- the composition may contain a flavorant.
- the flavorant may be a natural flavorant, an artificial flavorant, or a combination thereof.
- Preferred flavorants include, but are not limited to, natural lemon extract, artificial lemon extract, 10 natural orange extract, and any combination of any of the foregoing.
- the composition may contain an amount of flavorant effective in masking any degree of malodor remaining in the chondroitin-containing composition.
- the amount of flavorant in the composition broadly ranges from 0.0 to about 10 percent by weight based upon 100 percent by weight of total composition.
- the flavorant is present in the composition in an amount of about 3.3 percent by weight on the same basis.
- glucosamine or a salt thereof, may also be included in the composition.
- Preferred salts of glucosamine indude but are not limited to, glucosamine hydrochloride and glucosamine sulfate.
- the weight ratio of chondroitin sulfate to glucosamine generally ranges from about 1:100 to about 100:1.
- the typical mixture found in the composition which are currently commercialized have a weight ratio of about 5:4. Therefore, the preferred weight ratio of glucosamine to chondroitin is about 5:4.
- a preferred glucosamine is glucosamine hydrochloride, such as that produced by Wilke International of 15036 W. 106 th Street, Lexexa, Kans. 66215.
- composition may be incorporated into or formed into solid dosage forms, such as capsules or tablets.
- the claimed composition may be prepared by blending the chondroitin compound with citric acid, silicon dioxide, and optionally a flavorant.
- citric acid, silicon dioxide, and the flavorant are mixed to form a citric acid/silicon dioxide/flavorant mixture prior to blending with the chondroitin sulfate.
- the citric acid/silicon dioxide/flavorant mixture is preferably prepared by mixing silicon dioxide and the flavorant and then adding citric acid.
- Silicon dioxide (3.0 mg) available as Aerosil from Degussa-Huls Corporation of Ridgefield Park, N.J. was blended with 49.5 mg of natural lemon extract for about 3 minutes in a PK blender (manufactured by Patterson & Keely, a divison of Harsco Corporation, East Stroudsburg, Pa. 18301).
- Citric acid (22.5 mg) was added to the silicon dioxide/lemon extract blend and blended for about 2 minutes.
- a 5:4 mixture of glucosamine sulfate and chondroitin sulfate was prepared by mixing in a mixing bowl with a PK Blender 750 grams of glucosamine hydrochloride (marketed by Pfanstiehl Laboratory Inc. of 1219 Glen Rock Avenue, Waukegan, Ill. 60085) and 600 grams of chondroitin sulfate (marketed under the tradename Polychon® 60/40 by Vanson, Inc. of Waukegan, Ill.).
- the mixture was placed into the feed hopper of a Fitzpatric IR-520 Chilsonator.
- the chilsonator converted the mixture into a compacted solid.
- the chilsonator was operated at a roll speed of 6 rpm, roll pressure of 1250 psig, vertical screw speed of 150 rpm, and horizontal screw speed of 15 rpm.
- the compacted product formed in the chilsonator was passed through a Fitzpatric M5A mill and the granulated product collected.
- the mill was operated at a rotor speed of 300 rpm with a 4 bar rotor and a 0.050 inch rasping screen.
- the relative humidity was 57% and the temperature was 75° F.
- the chondroitin sulfate/glucosamine hydrochloride mixture, 30.0 mg of sodium starch glycolate, and 15.0 mg of magnesium stearate were added to the silicon dioxide/lemon extract/citric acid blend and blended for about 3 minutes.
- the resulting powder blend was then compressed into a tablet at a suitable compression pressure using a rotary tablet press and standard tooling.
- the resulting tablet did not exhibit any malodor, differing substantially from that exhibited by the initial chondroitin sulfate component.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method of removing or masking odor associated with chondroitin derived from marine life. The method comprises blending the chondroitin with citric acid, silicon dioxide, and optionally a flavorant to yield a substantially non-malodorous blend.
Description
- This application claims priority from provisional application No. 60/274806. filed Mar. 9, 2001, and is a divisional application of co-pending application Ser. No. 10/094,096.
- The present invention relates to a method for the removal or masking of malodor from chondroitin derived from marine life. The present invention also relates to chondroitin compositions derived from marine life which lack a malodor.
- Chondroitin and glucosamine are chondroprotective agents used for the treatment of osteoarthritis and related diseases. Chondroitin sulfate is a soluble mucopolysaccharide derived from bovine, ovine or shark cartilage. Chondroitin sulfate derived from marine life, such as cartilage isolated from sharks, provides a rich, pure, and readily absorbed source of chondroitin.
- Chondroitin sulfate has been reported to be effective in tissue repair and cartilage regeneration. Combinations of glucosamine and chondroitin are also effective in cartilage regeneration and joint maintenance. Chondroitin and glucosamine appear to act by increasing chondrocyte anabolic activity and suppressing degradative action of mediators on cartilage. This appears to facilitate natural tissue repair. See, e.g., H. Benedikt, Nat. Pharm., 1(8): 1, 22 (1997) and C. Bassleer, et al., Int. J. Tiss. Reac. XIV(5): 231-241: (1992). Additionally, chondroitin and glucosamine are believed to be safer and less toxic than steroids or non-steroidal anti-inflammatory drugs commonly administered to treat arthritis and related musculo-skeletal diseases.
- Although shark cartilage is rich source of chondroitin, shark-derived chondroitin has a strong malodor.
- Therefore, there is a need for compositions containing shark-derived chondroitin without its malodor and methods of preparing the same. Removal of the malodor associated with such chondroitin would improve consumer acceptability and enhance patient compliance.
- It is an object of the invention to provide a method for removing and/or reducing the malodor associated with chondroitin derived from marine life. It is further an object of the invention to provide chondroitin derived from marine life which exhibits reduced levels of malodor normally associated with such a composition.
- The invention relates to a method of removing or masking odor associated with chondroitin sulfate. The method comprises blending the chondroitin with citric acid, silicon dioxide, and, optionally a flavorant, to yield a substantially non-malodorous blend. The blend may be formed into a solid dosage form, such as a tablet.
- Another embodiment of the invention is a composition comprising chondroitin, citric acid, silicon dioxide, and an optional flavorant.
- The present inventors have discovered that the malodor associated with chondroitin derived from marine life may be removed or masked by blending the chondroitin with citric acid and silicon dioxide. Chondroitin compositions produced through the use of the present invention exhibit reduced levels of the malodor normally associated with such chondroitin compositions derived from marine sources
- The chondroitin may be any chondroitin-containing composition. Commonly available are two salts, namely chondroitin sulfate or chondroitin hydrochloride. Preferably, the chondroitin is the sulfate salt and is derived from shark cartilage. Most preferably, the chondroitin is water soluble, such as Polychon 60/40 available from Vanson, Inc. (Pfanstiehl Laboratory Inc.) of Waukegan, Ill.
- The amount of citric acid in the composition broadly ranges from about 0.05 to about 10% percent by weight based upon 100 percent by weight of total composition. Preferably, the amount of citric acid in the composition is about 1.5 percent by weight on the same basis.
- The amount of silicon dioxide in the composition ranges broadly from about 0.01 to about 2.0 percent by weight based upon 100 percent by weight of total composition. Preferably, the amount of silicon dioxide in the composition is preferably about 0.2 percent by weight on the same basis.
- Other adjuvants as known to those in the art, such as disintegrants, antioxidants, lubricants and binders, may be included in the composition.
- Optionally, the composition may contain a flavorant. The flavorant may be a natural flavorant, an artificial flavorant, or a combination thereof. Preferred flavorants include, but are not limited to, natural lemon extract, artificial lemon extract, 10 natural orange extract, and any combination of any of the foregoing. The composition may contain an amount of flavorant effective in masking any degree of malodor remaining in the chondroitin-containing composition. The amount of flavorant in the composition broadly ranges from 0.0 to about 10 percent by weight based upon 100 percent by weight of total composition. Preferably, the flavorant is present in the composition in an amount of about 3.3 percent by weight on the same basis.
- Combinations of chondroitin and glucosamine compounds are popular. Therefore, glucosamine or a salt thereof, may also be included in the composition. Preferred salts of glucosamine indude, but are not limited to, glucosamine hydrochloride and glucosamine sulfate. The weight ratio of chondroitin sulfate to glucosamine generally ranges from about 1:100 to about 100:1. The typical mixture found in the composition which are currently commercialized have a weight ratio of about 5:4. Therefore, the preferred weight ratio of glucosamine to chondroitin is about 5:4. A preferred glucosamine is glucosamine hydrochloride, such as that produced by Wilke International of 15036 W. 106th Street, Lexexa, Kans. 66215.
- The composition may be incorporated into or formed into solid dosage forms, such as capsules or tablets.
- The claimed composition may be prepared by blending the chondroitin compound with citric acid, silicon dioxide, and optionally a flavorant. Preferably, citric acid, silicon dioxide, and the flavorant are mixed to form a citric acid/silicon dioxide/flavorant mixture prior to blending with the chondroitin sulfate. The citric acid/silicon dioxide/flavorant mixture is preferably prepared by mixing silicon dioxide and the flavorant and then adding citric acid.
- The following example illustrates the invention without limitations. All amounts are by weight unless otherwise specified.
- Silicon dioxide (3.0 mg) available as Aerosil from Degussa-Huls Corporation of Ridgefield Park, N.J. was blended with 49.5 mg of natural lemon extract for about 3 minutes in a PK blender (manufactured by Patterson & Keely, a divison of Harsco Corporation, East Stroudsburg, Pa. 18301). Citric acid (22.5 mg) was added to the silicon dioxide/lemon extract blend and blended for about 2 minutes.
- A 5:4 mixture of glucosamine sulfate and chondroitin sulfate was prepared by mixing in a mixing bowl with a PK Blender 750 grams of glucosamine hydrochloride (marketed by Pfanstiehl Laboratory Inc. of 1219 Glen Rock Avenue, Waukegan, Ill. 60085) and 600 grams of chondroitin sulfate (marketed under the tradename Polychon® 60/40 by Vanson, Inc. of Waukegan, Ill.). The mixture was placed into the feed hopper of a Fitzpatric IR-520 Chilsonator. The chilsonator converted the mixture into a compacted solid. The chilsonator was operated at a roll speed of 6 rpm, roll pressure of 1250 psig, vertical screw speed of 150 rpm, and horizontal screw speed of 15 rpm. The compacted product formed in the chilsonator was passed through a Fitzpatric M5A mill and the granulated product collected. The mill was operated at a rotor speed of 300 rpm with a 4 bar rotor and a 0.050 inch rasping screen. The relative humidity was 57% and the temperature was 75° F.
- The chondroitin sulfate/glucosamine hydrochloride mixture, 30.0 mg of sodium starch glycolate, and 15.0 mg of magnesium stearate were added to the silicon dioxide/lemon extract/citric acid blend and blended for about 3 minutes. The resulting powder blend was then compressed into a tablet at a suitable compression pressure using a rotary tablet press and standard tooling. The resulting tablet did not exhibit any malodor, differing substantially from that exhibited by the initial chondroitin sulfate component.
- Many variations of the present invention will suggest themselves to those skilled in the art in light of the above, detailed description. All such obvious variations are within the full intended scope of the appended claims.
Claims (30)
1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. A composition exhibiting reduced malodor comprising
a. chondroitin derived from marine life;
b. citric acid, and
c. silicon dioxide.
16. The composition of claim 15 , wherein said chondroitin is chondroitin sulfate.
17. The composition of claim 15 , wherein said chondroitin is chondroitin sulfate derived from shark cartilage.
18. The composition of claim 15 , wherein the amount of citric acid ranges from about 0.5 to about 10 percent by weight based upon 100 percent by weight of the composition.
19. The composition of claim 16 , wherein the amount of citric acid is about 1.5 percent by weight, based upon 100 percent by weight of the composition.
20. The composition of claim 15 , wherein the amount of said silicon dioxide ranges from about 0.01 to about 2.0 percent by weight, based upon 100 percent by weight of the composition.
21. The composition of claim 6 , wherein the amount of said silicon dioxide is about 0.2 percent by weight, based upon 100 percent by weight of the composition.
22. The composition of claim 15 further comprising a flavorant.
23. The composition of claim 22 wherein said flavorant is selected from the group consisting of natural flavorants, artificial flavorants, or a combination thereof.
24. The composition of claim 22 wherein the flavorant is present in amount up to about 10 percent by weight, based upon 100 percent by weight of the composition.
25. The composition claim 22 wherein the flavorant is present in an amount of about 3.3 percent by weight, based upon 100 percent by weight of the composition.
26. The composition of claim 15 further comprising glucosamine or a salt thereof.
27. A composition of 26, wherein the weight ratio of glucosamine or salt thereof to chondroitin is about 5:4.
28. A solid dosage form comprising the composition of claim 15 .
29. A composition which does not exhibit malodor comprising chondroitin sulfate derived from marine life.
30. The composition of claim 29 wherein said chondroitin is derived from shark cartilage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/120,887 US20050256080A1 (en) | 2001-03-09 | 2005-05-03 | Method for reducing malodor of chondroitin |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27480601P | 2001-03-09 | 2001-03-09 | |
US10/094,096 US6906045B2 (en) | 2001-03-09 | 2002-03-08 | Method for reducing malodor of chondroitin |
US11/120,887 US20050256080A1 (en) | 2001-03-09 | 2005-05-03 | Method for reducing malodor of chondroitin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/094,096 Division US6906045B2 (en) | 2001-03-09 | 2002-03-08 | Method for reducing malodor of chondroitin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050256080A1 true US20050256080A1 (en) | 2005-11-17 |
Family
ID=26788386
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/094,096 Expired - Lifetime US6906045B2 (en) | 2001-03-09 | 2002-03-08 | Method for reducing malodor of chondroitin |
US11/120,887 Abandoned US20050256080A1 (en) | 2001-03-09 | 2005-05-03 | Method for reducing malodor of chondroitin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/094,096 Expired - Lifetime US6906045B2 (en) | 2001-03-09 | 2002-03-08 | Method for reducing malodor of chondroitin |
Country Status (1)
Country | Link |
---|---|
US (2) | US6906045B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016214215A (en) * | 2015-05-26 | 2016-12-22 | アピ株式会社 | Odor masking agent, capsule, and odor masking method |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101129346B (en) * | 2007-07-23 | 2010-09-29 | 重庆康刻尔制药有限公司 | Ambroxol hydrochloride oral cavity disintegrating tablet and method of producing the same |
US8741275B2 (en) | 2010-06-04 | 2014-06-03 | Robetet, Inc. | Malodor neutralizing compositions comprising undecylenic acid or citric acid |
WO2012103004A1 (en) | 2011-01-27 | 2012-08-02 | Robertet, Inc. | Malodor neutralizing compositions comprising bornyl acetate or isobornyl acetate |
US9114180B2 (en) | 2012-03-30 | 2015-08-25 | Robertet, Inc. | Malodor neutralizing compositions containing acids and alicyclic ketones |
CN103041430A (en) * | 2012-12-28 | 2013-04-17 | 青岛信锐德科技有限公司 | Healthcare air freshener |
CN103041431A (en) * | 2012-12-28 | 2013-04-17 | 青岛信锐德科技有限公司 | Air fresher with plant essential oil |
CN103041428A (en) * | 2012-12-28 | 2013-04-17 | 青岛信锐德科技有限公司 | Natural plant essential oil air purifying agent |
CN103041427A (en) * | 2012-12-28 | 2013-04-17 | 青岛信锐德科技有限公司 | Air fresher with bilberry extract |
CN103041429A (en) * | 2012-12-28 | 2013-04-17 | 青岛信锐德科技有限公司 | Non-toxic air freshener |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358539B1 (en) * | 1999-08-20 | 2002-03-19 | Howard Murad | Pharmaceutical compositions for reducing the appearance of cellulite |
-
2002
- 2002-03-08 US US10/094,096 patent/US6906045B2/en not_active Expired - Lifetime
-
2005
- 2005-05-03 US US11/120,887 patent/US20050256080A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358539B1 (en) * | 1999-08-20 | 2002-03-19 | Howard Murad | Pharmaceutical compositions for reducing the appearance of cellulite |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016214215A (en) * | 2015-05-26 | 2016-12-22 | アピ株式会社 | Odor masking agent, capsule, and odor masking method |
Also Published As
Publication number | Publication date |
---|---|
US20020141963A1 (en) | 2002-10-03 |
US6906045B2 (en) | 2005-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7495076B2 (en) | Mineral collagen chelates and methods of making and using same | |
US6906045B2 (en) | Method for reducing malodor of chondroitin | |
HK1084015A1 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2- | |
WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
SA94150373A (en) | Novel formulatons and to the use of forulation in the treatment and/or prvention of certain disorders | |
CN1178467A (en) | Polyphenol fractions of tea, the use thereof and formulations containing same | |
EP0545194A1 (en) | Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof | |
RU2004127960A (en) | APPLICATION OF VITAMIN D COMPOSITIONS | |
IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
HUT76325A (en) | Solid pharmaceutical compositions containing (s)-2-(4-isobutylphenyl) propionic acid active ingredient and microcrystalline cellulose and colloidal silica as excipients | |
KR102054942B1 (en) | Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility | |
RU2005141230A (en) | PHARMACEUTICAL COMPOSITION OF DESMOPRESSIN IN THE FORM OF A SOLID DOSED MEDICINAL FORM AND METHOD OF ITS PRODUCTION | |
JP5689458B2 (en) | Methods for stabilizing dietary supplements containing glucosamine | |
AU7532994A (en) | Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt | |
AT392002B (en) | USE OF PEROXYDIPHOSPHATES FOR THE PRODUCTION OF PHARMACEUTICAL TABLETS OR. PHARMACEUTICAL AQUEOUS SOLUTIONS | |
NZ207930A (en) | Preparing base salts of piroxicam | |
AU776522B2 (en) | Fosinopril sodium tablet formulation | |
DK201000616A (en) | Compositions consisting of or being enriched with seeds of rose hips and their use as anti-flammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis | |
CN1762354A (en) | A stable pharmaceutical composition containing a calcium blocker | |
JP4850402B2 (en) | Oral preparation | |
EP1818050A1 (en) | Stable pharmaceutical compositions comprising a HMG-CoA reductase inhibitor | |
JP2001314173A (en) | Composition for food | |
JP2006271267A (en) | Dietary supplement having deodorant function | |
WO2023074896A1 (en) | Pharmaceutical or food composition | |
JP3947244B2 (en) | Preparation for peptic ulcer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |